|Bid||95.55 x 200|
|Ask||127.00 x 1000|
|Day's Range||114.27 - 118.34|
|52 Week Range||31.38 - 126.16|
|PE Ratio (TTM)||-22.57|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vir Biotechnology, a San Francisco-based startup led by former Biogen CEO George Scangos, said Wednesday that it will work with Alnylam Pharmaceuticals to develop infectious disease treatments using the Cambridge company’s experimental technology. Under the agreement, the companies will collaborate to develop one of Alnylam’s (ALNY) potential drugs for hepatitis B, plus up to four additional treatments for infectious diseases. Alnylam will be eligible to receive over $1 billion in payments if the drugs hit certain milestones.
Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease. The partnership with Vir includes development of drugs for four other infectious diseases using RNAi technology, which aims to silence targeted genes to curb the production of disease-causing proteins and have limited side-effects. Under the deal, the drug developer would receive an undisclosed upfront payment and more than $1 billion in potential milestone payments among other things.
Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B. Alnylam said it would receive an upfront payment, comprising cash and Vir's shares under the deal terms, and would be eligible for more than $1 billion in potential milestone payments among other things. The company also said it would terminate development of its hepatitis B drug and would work on a new treatment along with Vir for the disease, apart from collaborating on therapies for four other infectious diseases.
Alnylam Pharmaceuticals Inc. said Wednesday it has entered into an exclusive license agreement with privately-held Vir Biotechnology to develop and sell RNAi therapeutics for infectious diseases, including ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.
Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
Alnylam could enter a new chapter in 2018 as it transitions into a commercial-stage company, an analyst said Thursday.
When a small drug company’s surges almost 52% in a single day after releasing impressive clinical trial results for a potentially revolutionary class of drugs, should investors cash in or go all in? In the case of Alnylam Pharmaceuticals (ALNY), the answer depends on which sell-side analyst happens to be speaking. Instinet’s Christopher Marai advises investors to “sell on the data.” The strong late-stage study results released yesterday for the company’s Patisiran therapy, a RNAi therapeutic, are already baked into the stock price, which sat almost unchanged today at $113.52 a share.
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Alnylam Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Alnylam Pharmaceuticals (ALNY) saw a big move last session, as its shares jumped nearly 52% on the day, amid huge volumes.
Many companies backed away from the gene silencing technique when big investments in the field didn’t pan out — but not Alnylam.
Alnylam Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Based on the stellar results and clean safety profile, we think patisiran will likely receive approval in the U.S. and Europe in 2018, which drives our fair value change and peak sales estimates near $1 ...
On a day stocks gyrated in response to Federal Reserve announcements, Bed Bath & Beyond fell sharply on earnings, and Alnylam Pharmaceuticals soared on a successful drug trial.
Alnylam Pharmaceuticals CEO John Maraganore discusses his company's successful drug trial to treat a rare nerve disorder, and what he sees for the underlying technology. With CNBC's Meg Tirrell.